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Thymus-derived lymphocytes (T cells)  play central roles in immune responses. They 
include effector cells in cell-mediated immune responses such as delayed-type hypersensi- 
tivity (DTH), ~ altograft rejection, tumor immunity and cellular resistance to infection, 
mediate helper function in antibody production, and act as suppressor cells in both cell- 
mediated and humoral immune responses (1, 2). At present these T-cell-mediated func- 
tions are studied with various functional assay systems such as killing of target cells (3), 
production of lymphokines (4), proliferative T-cell  response (5), or carrier effect in anti- 
body production  (6). These  assay systems contributed much in the  elucidation of the 
nature  of T-cell-mediated  functions.  However,  all  of these  methods  are  restricted  to 
measure the activities of a certain cell population. The development of more quantitative 
methods has been desired which would enable us to enumerate antigen-specific T cells at 
the single cell level analogous to Jerne plaque assay for antibody-producing cells. 
Bloom et al.  (7)  introduced a  hopeful method to enumerate activated T cells.  They 
showed that the antigen-reactive lymphocytes became capable of replicating vesicular 
stomatitis virus (VSV) when lymph node cells from guinea pigs showing DTH to tuber- 
culin  were cultured in  vitro  with  purified  protein  derivative  of tuberculin  (PPD).  As 
VSV-replicating cells were not observed in the culture of lymph node cells taken from the 
animals that were immunized so as to produce antibody against PPD without accom- 
panying DTH, it was strongly suggested that antigen-induced virus plaque-forming cells 
(V-PFC) represented the lymphocytes involved in DTH. Subsequently, Kano et al.  (8, 9) 
showed that V-PFC were generated in the mitogen-stimulated culture of normal mouse 
lymphocytes or in the mixed lymphocyte culture,  and that these V-PFC belonged to T 
cells.  Thus, it has been expected that this new method might be useful as a tool for the 
enumeration of antigen-reactive T cells.  However, there still remain at least two prob- 
lems for virus plaque assay before it can be used generally.  The first one is whether 
antigen-induced V-PFC can be detected in the immune responses to any other antigens, 
especially to those widely used in the study of both humoral and cell-mediated immune 
responses. The other is whether virus plaque assay measures all the activated T lympho- 
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cytes or only a  subpopulation  of T  lymphocytes, such  as effector cells,  helper cells, or 
other cells involved in the regulation of immune responses. 
In the present study, we attempted to apply virus plaque assay to analyze the 
immune  response of mice against the widely used antigen, sheep red blood cells 
(SRBC), since in this experimental system we would most easily be able to deal 
with  both  humoral  and  cell-mediated  immune  responses  simultaneously.  T 
lymphocytes which acquired the capacity to produce VSV by antigenic stimula- 
tion (Ag-V-PFC) were generated in the culture of spleen cells from mice that had 
been primed with SRBC. These Ag-V-PFC detected in our experimental system 
did not seem to represent the helper cells nor the effector cells mediating  DTH, 
but  seemed  to  represent  SRBC-reactive T  cells  involved in  the  regulation  of 
DTH. 
Materials and Methods 
Animals and Immunization.  Male CBA/StMs mice originally obtained from National Insti- 
tute of Genetics, Mishima, Japan, aged 8- to 10-weeks old, were used throughout the experiments. 
Mice were immunized with SRBC by intravenous injection via the tail vein. 
Conjugation of 2,4,6-Trinitrophenol  (TNP) to Erythrocytes.  Heavily conjugated TNP-SRBC 
was  prepared  according to  Kettman  and  Dutton  (10) for in  vitro assay  of carrier effect.  The 
preparation  of TNP-conjugated horse  red  blood  cells  (TNP-HRBC)  for the  assay  of anti-TNP 
plaque-forming cells was essentially the same as that reported by Rittenberg and Pratt (11). 
Cell Suspensions and Culture.  Spleen cell suspensions were prepared as described previously 
(12). After washings,  the cells were resuspended in Eagle's minimal essential medium (MEM) 
(Nissui Seiyaku, Japan) supplemented with 8% heat-inactivated fetal calf serum (Flow Laborato- 
ries, Inc., RockviUe, Md.), and 5 × 10  -5 M 2-mercaptoethanol. The cell concentration was adjusted 
to 1.2  ×  107 viable cells per ml, and 1.5 ml of the cells was cultured per dish.  For virus plaque 
assay, the cells were cultured with 1 x 10  ~  SRBC in 35-mm plastic dishes (Falcon Plastics, Oxnard, 
Calif.). In the experiment to test the cross-reactivity, 1 x  107 HRBC were also used as the in vitro 
antigen.  For the assay  of helper T-cell activity, the cells were cultured with  1  ×  107 heavily 
conjugated TNP-SRBC. In all experiments, control cultures were also set up parallely in antigen- 
free medium. They were incubated at 37°C in 5% CO2 in humidified air. 
Antisera.  Mouse anti-SRBC serum was obtained from mice given intravenous injection of 109 
SRBC 4 days previously and heated at 56°C for 30 rain.  This unabsorbed serum (hemagglutinin 
titer 1:1,024) was called US4 according to Mackaness et.al. (13). The US4 was absorbed three times 
with equal volume of packed SRBC. This absorbed serum was called AS4, the hemagglutinin titer 
of which was lower than 1:2. 
Rabbit anti-mouse thymocyte serum (ATS) was prepared as described previously (14). After the 
incubation of cells (final l0  T  per ml) with ATS (final 1:100) and guinea pig serum (final 1:10) at 37°C 
for 45 min, more than 95% of the thymocytes, 37-53% of the spleen cells, and less than 5% of the 
bone marrow cells were killed. Even with 1:5 dilution of ATS, killing of bone marrow cells did not 
increase. 
Assay of Antibody-Producing Cells.  Antibody-forming cells were assayed as PFC in agarose 
gel on microslides (15). Anti-TNP antibody-forming cells were assayed using TNP-HRBC. Anti- 
mouse immunoglobulin rabbit serum (1:200) was used to develop indirect PFC. 
Test for DTH.  Procedures of the injection of test antigen into the footpads and the measure- 
ment of the swelling were essentially the same as those used in the previous study on DTH to 
bovine serum albumin (14). DTH to SRBC was estimated by the swelling of one footpad 24 h after 
the injection of 1 × l0  s SRBC. In one experiment, an eliciting dose of HRBC was injected into one 
footpad  to check the cross-reactivity. 
Virus Plaque Assay 
VIR~S.  VSV,  New Jersey strain,  was supplied from National Institute of Animal Health, 
Tokyo, Japan. They were grown in L cells and stored at -70°C after centrifugation to remove cell 392  VIRUS-REPLICATING T  CELLS.  I. 
debris. After thawing, virus was titrated by plaque technique and expressed as plaque-forming 
units (PFU). 
L  CELLS.  L-158 cells were maintained continuously in Roux bottles in MEM supplemented 
with 5% calf  serum (CS). For the virus plaque assay, 1 × l0  s cells in 2 ml of MEM containing 5% CS 
were plated in 35-mm plastic dishes 24 h before use, and incubated at 37°C in 5% CO2 in air. At the 
time of assay, the plates used had a confluent monolayer of L cells. 
ANT]-VSV SERUM.  Rabbit anti-VSV serum was kindly supplied by Dr. G. Tokuda (National 
Institute of Animal Health).  The serum was inactivated at 56°C for 30 rain, filtered through 
Millipere filter, and stored at -20°C. The serum (final 1:10) was found to be able to neutralize at 
least 1 x  l0  s PFU of VSV. 
VIRUS PLAQUE J~SSAY.  Cultured spleen cells were washed, resuspended in MEM, and adjusted 
to 2-3 x  10  e cells per 0.2 ml. 0.2 ml of cell suspensions were infected with VSV and incubated at 
37°C in 5% CO~ in air for 2 h. The multiplicity of infection was about 30.  Excess viruses were 
removed by two washings, and the remaining free viruses were neutralized by incubating the cell 
suspensions (0.5 ml) with 0.05 ml of anti-VSV serum at 4°C for 1 h. After three further washings, 
cell suspensions were adjusted to 1 ×  105 cells per ml. The medium of the monolayers of L cells 
were drained, and 0.1 ml of VSV-infected cells (1 × 104) were added on the monolayers. Then 0.4 ml 
of 1% agar in MEM containing 6% CS, maintained at 42-44°C, was poured and mixed gently with 
the cells. After this layer of agar had solidified, another layer of 1 ml warm agar-MEM was added 
as a nutrient layer. Each cell sample was plated in triplicate. Samples of the supernate of the final 
centrifugation of VSV-infected lymphocytes were also plated. Since these supernatant samples did 
not contain viruses, virus plaques appearing in the L-cell monolayers were regarded as plaques by 
virus replicated in cells. The dishes were incubated at 37°C in 5% CO2 in air for 2 days, and then 
vitally stained with neutral red (1:10,000) in phosphate-buffered saline. 
C^LCULATION OF AG-V-P~.  Since there existed inevitable background V-PFC in the control 
cultures (1,000-4,000/10 s plated cells), we determined Ag-V-PFC as follows according to Kano et 
al. (9). Ag-V-PFC =  (V-PFC in the antigen-stimulated culture) -  (V-PFC in the control culture 
without antigen). Thus, Ag-V-PFC are cells that newly acquired the capacity for replicating VSV 
by antigenic stimulation. It was shown by Nowakowski et al.  (16) that almost all of the back- 
ground V-PFC were macrophages. 
Results 
Generation of V.PFC in the Culture of Spleen Cells from Mice Primed with 
SRBC.  Spleen cells from normal  mice or mice primed 5  days previously with 
varying  doses  (10  ~,  107,  or 109)  of SRBC  were cultured  with or without  SRBC. 
Cultured  cells were harvested  1,  2,  or 3,  days later, and virus-replicating cells 
were enumerated  on L-cell monolayers.  The results of the generation  of Ag-V- 
PFC in the culture are shown in Fig. 1 with solid lines. Each point in the figure 
represents  the  mean  Ag-V-PFC  of 2-6  separate  experiments.  In each  experi- 
ment,  two cultures were pooled, and a  triplicate plating for virus plaque assay 
was performed. In normal, unprimed  spleen cells, a  significant number  of Ag-V- 
PFC  was not generated  during  3  days in the culture  (Fig.  1 A). Increase in V- 
PFC by antigen  stimulation  was seen in the cultures of cells from primed mice, 
while the kinetic patterns  of generation  differed in relation to the immunizing 
doses. In the cultures of spleen cells from mice primed with relatively low doses 
ofSRBC  (10  ~ or 107),  the number  of Ag-V-PFC increased for 2 days, and this was 
followed by a rather  abrupt decrease (Fig. 1 B  and C). By contrast, the number  of 
Ag-V-PFC in the  spleen cell culture  of mice primed with a  high dose of SRBC 
(109) was maximal  on the 1st day and gradually declined thereafter  (Fig. 1 D). 
In the previous paper (17), it was shown that the kinetics of generation of Ag- 
V-PFC  in the culture  was quite different from that  of anti-SRBC  PFC.  In the 
present experiments,  generation of Ag-V-PFC was compared with that of helper NAGAHIRO  MINATO  AND  YOSHIMOTO  KATSURA  393 
',.J  Q.. 
I,  Q.. 
G_ 
t 
~r,  c: 
6.000 
4,000 
2,000 
(A)  (8) 
t 
I  2  5  4 
,li 
/ 
/ 
/ 
/  #li 
i  i "/  I  | 
I  2  3  4 
8,000 
6pO0 
4,000 
2,000 
(c)  ¢ 
/ 
/ 
i  s 
,, ,  "I'I 
// 
i  ~lr"  I  L 
I  2  3  4 
(D) 
I  2  3  4 
Days  in  cuHure 
Fza. I.  Kinetics of  the generation of  Ag-V-PFC and  anti-TNP PFC in  the  culture  of  spleen 
cells.  Spleen cells  from normal mice (A),  or mice primed with 10  5  (B),  10' (C),  or 10  0 (D) of 
SRBC were cultured with or  without the addition of  SRBC for  virus plaque assay,  and with 
heavily conjugated TNP-SRBC  for  helper assay. Virus plaque assay was performed on day 
1,  2, and 3 of  culture,  and the numbers of  Ag-V-PFC (©--©) were calculhted  as described in 
Materials and Methods. Each point represents arithmetic mean value of  Ag-V-PFC from 
two to six separate experiments. For each experiment, a triplicate  plating was performed. 
Direct (A---A)  and indirect  (A---A)  anti-TNP PFC were assessed on  day  2,  3,  and 4  of  culture 
of  the spleen cells  taken from the same mice as used in  one of  the  virus  plaque assays.  Each 
point represents the arithmetic mean value of  three cultures. 
T-cell activity. Spleen cells taken from the same mice used in one of the V-PFC 
experiments were cultured with or without the addition of heavily conjugated 
TNP-SRBC. Anti-TNP PFC response was assayed on day 2, 3, or 4. As shown in 
Fig.  1 with broken lines,  helper activity was induced significantly by priming 
with relatively low doses of SRBC (105 or 107) rather than with high dose (109), 
conforming to the data reported by Falkoffet al. (18). According to Lagrange et 
al. (19), DTH against SRBC was induced by intravenous immunization in which 
the immunization  with lower doses of SRBC (105 or 107) was more effective in 
producing DTH than the high dose (109). Similar results were also obtained by 
us in CBA mice (data not shown). Thus, as far as the requirement of the priming 
dose is concerned,  the  generation  of Ag-V-PFC  seems to  correlate  with both 
helper activity and DTH. 
ATS Sensitivity of  Ag-V-PFC.  In the preceding publication, we showed that 
the treatment of primed spleen cells before culture with ATS (1:100) plus guinea 
pig serum  (C') completely abolished  (about 97%)  the generation  of Ag-V-PFC 394 
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Fro.  2.  Abrogation of Ag-V-PFC by the treatment of cultured cells with ATS and guinea 
pig serum (C').  Spleen cells from mice primed with 107  SRBC  4 days  (A)  or 5 days  (B) 
previously were cultured with or without SRBC for 2 days. The cultured cells were infected 
with VSV, and 107 of infected cells were treated with ATS (final 1:100-1:25)  or NRS (final 
1:50) plus C'. The mean and each value of Ag-V-PFC of two cultures are shown. The same 
spleen cells as used for virus plaque assay were cultured for 4 days, and the effect of ATS 
treatment on antibody-producing  cells was also tested (C).  (D), direct anti-SRBC PFC; (@), 
indirect anti-SRBC PFC. Mean value ±  standard error of three cultures are shown. 
without  affecting the  background  level  of V-PFC  (17).  The  following experi- 
ments were performed to investigate whether or not the Ag-V-PFC generating 
in the culture were indeed T  cells.  Spleen cells from mice primed 4 or 5 days 
previously with 107 SRBC were cultured with or without SRBC for 2 days. The 
cultured cells were treated with ATS plus C' or normal rabbit serum (NRS) plus 
C', and then the virus plaque assay was performed. As shown in Fig. 2 A and B, 
treatment with ATS (1:50-1:25) eliminated 80-90% of Ag-V-PFC. Background V- 
PFC (about 600/106 treated cells) were scarcely affected by the same treatment. 
Since ATS used here never injured B cells (14) nor anti-SRBC PFC (Fig. 2 C), it 
was strongly suggested that most of Ag-V-PFC belonged to T-cell population. A 
lower concentration of ATS (1:100) was not sufficient enough to eliminate Ag-V- 
PFC. 
Antigen Specificity of Ag-V-PFC.  Spleen  cells  from  mice  primed  5  days 
previously with  l0  T SRBC  were  cultured  in  the  presence  of either  SRBC  or 
HRBC, or without the addition of antigen. Virus plaque assay was performed on 
the 2nd day, and antibody response to both SRBC and HRBC were assayed on 
the 4th day. 
A  considerable  number  of Ag-V-PFC  was  generated  in  HRBC-stimulated 
culture,  the  level of Ag-V-PFC  being about 40%  of that  in  SRBC-stimulated 
culture  (Table  I).  Anti-HRBC  antibody  response  was  also  observed  in  the NAGAHIRO  MINATO  AND  YOSHIMOTO  KATSURA  395 
TABLE  I 
Cross-Reactivity  at the Level of Ag-V-PFC for SRBC vs. HRBC* 
Ag-V-PFC/10  ~  Percent cross-re- 
In vitro Ag  V-PFC/10  6 plated cells*  plated cells§  action 
None  1,138 -+  186  -  - 
SRBC  9,000 -+  1,298  7,862  100 
HRBC  4,483  -+ 911  3,345  42 
* Spleen cells from mice primed intravenously with 107 SRBC 5 days previously were cultured in 
the presence of 107 SRBC or 10  ~ HRBC, or in the absence of antigen. 2 days after culture, a  V- 
PFC assay was performed. 
* The data  are expressed as the mean value of V-PFC  ±  the standard error  of the mean for 
triplicate culture. 
§ Ag-V-PFC was calculated as described in Materials and Methods. 
TABLE  II 
Antigen Specificity in Anti-SRBC Antibody Response* 
In vitro Ag 
Anti-SRBC PFC/culture*  Anti-HRBC PFC/culture* 
Direct  Indirect  Direct  Indirect 
None  460  ±  120  380  +- 76  167 +_ 47  7 ±  7 
SRBC  8,853 +- 350  5,733  ±  228  100 ±  12  13 ±  7 
HRBC  360 ±  64  430  ±  72  1,300  __ 220  200  ±  15 
Percent cross-  0  0.9 
reaction 
* Spleen cells from mice primed intravenously with l0  T  SRBC 5 days previously were cultured in 
the presence of 10  7 SRBC or 10  7 HRBC, or in the absence of antigen. 4 days after culture, anti- 
SRBC PFC and anti-HRBC PFC were assayed. 
Each value represents  the mean ofPFC ± the standard error of  the mean for triplicate culture. 
HRBC-stimulated  culture  of SRBC-primed  spleen  cells  (Table  II).  This  may 
probably be attributable  to the cross-reaction at the helper T-cell level,  since 
primary anti-HRBC PFC response was not observed in these culture conditions 
(data not shown),  and  since no cross-reaction was found at the  level of PFC 
(Table II). Thus, it was suggested that the cross-reactivity of helper T cells for 
SRBC vs. HRBC was about 10%. 
Cross-reactivity  of DTH for  SRBC  vs.  HRBC  was  also investigated.  Mice 
primed with an intravenous injection of 107 SRBC 3 days previously, and normal 
mice as the control,  were challenged  with  108 SRBC into one footpad and  10  s 
HRBC into the other footpad. The swelling was measured 24 h  later,  and the 
results were shown in Table III.  Delayed reaction to HRBC was about 20% of 
that to SRBC. 
These observations suggested that the degree of cross-reactivity in Ag-V-PFC 
for SRBC vs. HRBC may be comparable to or greater than that in helper T-cell 
activity or in DTH. 
Effect  of Antiserum  on  the In  Vitro  Generation  of Ag-V-PFC.  It  is  well 
known that the development of anti-SRBC antibody-forming cells is suppressed 
by specific antibody  without  affecting  the  generation  of helper  T  cells  (20). 
Recently it  was shown by Lagrange  et al.  (19) that  DTH to SRBC was sup- 396  VIRUS-REPLICATING  T  CELLS.  I. 
TABLE  III 
Cross-Reactivity  at the Level of DTH for SRBC and HRBC* 
Footpad swelling at 24 h  (1/lO mm)$  Net swell-  Percent 
Test Ag  cross-reac- 
Normal mice  Primed mice  ing  tion 
SRBC  3.0  ___  0.29  8.0  _+  1.02  5.0  100 
HRBC  2.86  -+ 0.38  4.0  +_  0.35  1.14  23 
* Mice were immunized intravenously with 107 SRBC or injected with saline as the control. 3 days 
later, an eliciting dose ~1  ×  108) of SRBC was injected into one footpad and the same dose of 
HRBC into the other footpad. Footpad swellings were measured 24 h later and expressed in the 
unit of X/lo mm. 
The data are expressed as mean of  the swellings _+ the standard error of  the mean for four mice. 
pressed  by anti-SRBC  serum  when given  either  induction or  manifestation 
phase.  In the latter experiments, absorbed anti-SRBC serum  (absorbed with 
SRBC) was more effective than native anti-SRBC serum (19). Thus, it seemed to 
be a hopeful clue for the characterization of  Ag-V-PFC to investigate the effect of 
anti-SRBC serum or the absorbed serum.  Spleen cells were taken from mice 
primed by an intravenous injection of 107 SRBC 5 days previously and cultured 
in the absence or in the presence of SRBC or heavily conjugated TNP-SRBC. 
Anti-SRBC serum (US4) or absorbed antiserum (AS4), prepared as described in 
Materials  and  Methods,  was  added  to  the  culture  medium  at  the  onset  of 
culture. Virus plaque assay was performed 2 days after the culture, and anti- 
TNP and anti-SRBC PFC were assessed on day 4. The results are shown in Fig. 
3. High concentration of  US4 (2.5%) completely suppressed the generation of Ag- 
V-PFC, while the same concentration of AS4 had no significant effect (Fig. 3 C). 
On the other hand, helper T-cell activity was not suppressed by the same dose of 
US4,  but  was rather "apparently" enhanced (Fig.  3 B).  Anti-SRBC  antibody 
response was suppressed by both US4 and AS4. These results suggested but did 
not prove that the antigen-specific T cell detected as Ag-V-PFC did not represent 
the helper T cell itself. 
Effect of Cyclophosphamide  (CY) Pretreatment.  Injection of CY before the 
immunization is known to enhance DTH against SRBC in mice (21), or against 
protein antigens in guinea pigs (22). If Ag-V-PFC represent effector T cells in 
DTH,  it can be expected that the generation of Ag-V-PFC may be greater in 
spleen cells from CY-pretreated mice than in those from CY-nontreated mice, 
since spleen cells from CY-pretreated mice are far more effective in transferring 
DTH to normal mice (21). CY (200 mg/kg) was injected intravenously into mice 2 
days before immunization with 107 SRBC. Control mice were given an injection 
of saline instead of CY. 6 days after immunization, spleen cells were harvested 
and cultured with or without SRBC for virus plaque assay, as well as for the 
assay of anti-SRBC antibody response. DTH was assayed simultaneously in the 
separate groups of mice. 
DTH on the 6th day after immunization was markedly augmented by the 
pretreatment with CY (Fig. 4 C), conforming to the data obtained by Lagrange 
and Mackaness (21). On the other hand, the number of Ag-V-PFC in the culture 
of spleen cells from CY-pretreated mice was only slight (Fig. 4 A).  The results 
shown in Fig.  4 B  indicated that anti-SRBC antibody response was also pro- NAGAHIRO  MINATO  AND  YOSHIMOTO  KATSURA  397 
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Fro. 3.  Effects  of  anti-SRBC serum (US4) or  absorbed anti-SRBC serum with  SRBC (AS4) 
on the generation of anti-SRBC PFC (A),  anti-TNP PFC (B),  and Ag-V-PFC  (C).  Spleen 
cells  from mice primed with 107 SRBC  5 days previously were cultured in the absence or 
presence of  SRBC or heavily conjugated TNP-SRBC. At the onset of  culture,  US4 (final  2.5 
or 0.25%), AS4 (final  2.5 or 0.25%), or medium  (MEM) as the control was added in the 
cultures. Virus plaque assay was performed on the 2nd day of  culture,  and anti-SRBC and 
anti-TNP PFC were assessed on the 4th day. Each value represents the mean of three 
cultures. 
hibited by CY pretreatment.  These experiments  revealed the absolutely con- 
trary effect of CY upon the development of T  cells detected as Ag-V-PFC and 
that  of DTH,  suggesting the  quite different  nature  of Ag-V-PFC  from  DTH- 
mediating effector T cells. 
Kinetic Study of the Development  of Ag-V-PFC after Immunization.  The 
following experiments were performed to investigate the development of T cells 
detected as Ag-V-PFC after immunization in reference to DTH. Mice were given 
an intravenous injection of 105, 107, or 109 SRBC and killed various days after 
immunization.  Their  spleen  cells  were  cultured  for  2  days  with  or  without 
SRBC,  and  then  virus  assay  was  performed.  DTH  was  also  checked in  the 
separate groups of mice. Results are shown in Figs. 5-7. In these figures, levels 
of Ag-V-PFC are recorded against the day when the spleen cells were harvested, 
and delayed reactions are recorded against the day when the test antigen was 
injected into the footpad. In the group of mice primed with 10  ~ SRBC, the peak 
level of DTH was  attained  on the  4th day after  immunization,  and  declined 
thereafter (Fig. 5). In contrast, Ag-V-PFC seemed to develop after DTH dimin- 
ished, and attained the peak on the 8th day. The high level of Ag-V-PFC seemed 398  VIRUS-REPLICATING  T  CELLS.  I. 
&O00 - 
59oo- 
~  3,ooo- 
u 
tJ_ 
13_ 
I 
~oocb 
(A)  ?,000 
5DO0 
4,ooo 
£9 
LI.,. 
o._  3,000 
[]3 
Q:: 
U') 
I,O00 
(8) 
[~  ~ 
CY  CY  CY  CY 
(-)  (+)  (-)  (+) 
8 
A 
E  7 
o 
6 
5 
0 
4 
,...£ 
3 
c~  2 
9  (C) 
I 
I 
CY  CY 
(-)  (+) 
Fro.  4.  Abrogation of the development of Ag-V-PFC by a  pretreatment with CY.  Mice 
were injected intravenously with CY (200 mg-kg -~) or saline and 2 days later immunized 
intravenously with l0  T  SRBC. 6 days after immunization, spleen cells were cultured with or 
without the addition of SRBC. Ag-V-PFC (A) were assayed on the 2nd day of culture, and 
anti-SRBC PFC  (B) were assayed on the 4th day. DTH  (C) was also assayed 6 days after 
immunization. In (A) and (B), the mean and each value of two cultures are shown. In (C), 
the mean and the range of standard error are shown. 
to be sustained rather a long time after immunization, the number being about 
2,000 per 106 plated cells on the 16th day. 
The levels and kinetic patterns of development of both DTH and Ag-V-PFC in 
mice primed with l0  T  SRBC resembled those in mice primed with 105 SRBC (Fig. 
6). Only the time span of  the latent phase seemed to be 2-3 days shorter. In mice 
primed with 109 SRBC, Ag-V-PFC began to develop as early as the 2nd day and 
attained  the peak on the 4th  day after immunization,  though  DTH was not 
conspicuously detected in this group  (Fig.  7).  The level of Ag-V-PFC declined 
thereafter to become undetectable by day 16. 
Discussion 
The  development  of the  virus-replicating  lymphocytes was  studied  in  the 
immune response of mice to SRBC. Cells that acquired the capacity to replicate 
VSV by antigenic  stimulation  (Ag-V-PFC) were generated  in  the  culture  of 
spleen cells from mice immunized with SRBC. In the previous paper (17), it was 
shown that the generation of  Ag-V-PFC in vitro was completely abolished by the 
treatment of primed spleen cells with ATS plus C' before culture. Experiments 
presented  here  showed  that  treatment  of cultured  cells  with  ATS  plus  C' 
eliminated 80-90% of Ag-V-PFC. Thus, it was revealed that most of Ag-V-PFC "O 
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Kinetics of the development of Ag-V-PFC and DTH ai~r the intravenous injection 
of 10  5 SRBC.  Mice were immunized  with 10  5 SRBC,  and various days after immunization 
spleen cells were cultured with or without SRBC. Virus plaque assay was performed after 2 
days of culture. DTH was also assayed in the separate group of mice. The level of Ag-V-PFC 
(©--©) was recorded against the day when spleen cell culture was set up,  and DTH  (~) 
was recorded  against the day when eliciting dose of SRBC  was injected  into the footpad. 
Hatched area of the column represents the background  swelling,  i.e.,  footpad swelling of 
nonprimed mice by an eliciting dose of SRBC. 
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FIG.  6.  Kinetics of the development of Ag-V-PFC and DTH after the intravenous injection 
of 10  7 SRBC.  Experimental  protocol and indications are the same as in Fig.  5. 
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FIG.  7.  Kinetics of the development of Ag-V-PFC and DTH after the intravenous injection 
of 10  ° SRBC.  Experimental protocol and indications are the same as in Fig. 5. 
indeed belonged to T-cell  population.  It  was noted  here  that  two to fourfold 
higher concentration of ATS was required for the almost complete elimination of 
Ag-V-PFC in the case of cultured spleen cells compared with the case of spleen 
cells before culture.  This is consistent with the findings that activated T  cells 
were more resistant to immune cytolysis by anti-0 treatment  (8, 23). 
"Broad" cross-reaction (about 40%) for SRBC vs. HRBC in the generation of 
Ag-V-PFC  (Table I) confirmed that Ag-V-PFC belonged to T  cells, since little 
cross-reaction was observed at the level of antibody response (Table II). "Broad" 
cross-reactivity between heterologous erythrocytes at the level of T  cells was 
also observed by other investigators in various assay systems, such as rosette- 
forming cells  (24),  killer cells (25),  DTH (25),  and helper cells (25,  26).  In our 
present experiments,  the degree of cross-reactivity of Ag-V-PFC for SRBC vs. 
HRBC was comparable to or greater than that of DTH (about 20%) or that of 
helper activity (about 10%). 
The kinetic patterns  of the  generation  of Ag-V-PFC in the  culture  (Fig.  1) 
were  quite  different  from the  pattern  observed in  the  virus  plaque  assay of 
lymphocytes from  tuberculin  hypersensitive  donors  stimulated  with  PPD  in 
vitro  (7),  in  which linear  increase  of Ag-V-PFC  was seen for at least 4 days 
during the culture. If we accept that the antigen-reactive lymphocytes detected 
by Bloom et al.  (7) and those detected by us belong to the same cell population, 
the difference in the pattern of the generation in vitro may be attributable to the 
difference in the experimental  systems,  such as antigens or animals  used.  It 
seemed unlikely that the decline of Ag-V-PFC by the  3rd day in the  present 
study was ascribed to the non-specific cell death during the culture,  since the 
cell viability of the 2nd and the 3rd day did not differ so much, about 40-50% of 
cells being viable on these days. Thus, the decline of Ag-V-PFC by the 3rd day NAGAHIRO  MINATO  AND  YOSHIMOTO  KATSURA  401 
may be explained by either or all of the following:  (a) The cells responsible for 
Ag-V-PFC  in  SRBC-stimulated  cultures  were  exhausted rapidly under the 
sustained antigenic stimulation in vitro.  (b) As suggested by Kano et al.  (9), 
replication of VSV occurred maximally in the earlier restricted stage of lympho- 
cyte activation.  (c) Specific  antibody produced in the culture inactivated the 
lymphocytes responsible for Ag-V-PFC. We have not investigated whether the 
first or the second possibility may explain the rather abrupt reduction of Ag-V- 
PFC during 3 days. However, the third possibility was thought to explain the 
characteristic pattern observed in our experiments, because anti-SRBC  anti- 
body was shown to be produced in the culture (17), and passively administered 
anti-SRBC antiserum in the cultures almost completely suppressed the genera- 
tion of Ag-V-PFC (Fig. 3). It is probable that the linear increase of PPD-reactive 
V-PFC  observed by  Bloom et  al.  (7)  might have resulted from lack  of the 
production of specific  antibody affecting VSV-replicating lymphocytes in the 
culture. Thus, we may be allowed at present to consider that Ag-V-PFC detected 
in the present experiments and those by Bloom et al.  (7) belong to the same 
population of cells, until experimental evidence against such an assumption are 
adduced. 
The generation of Ag-V-PFC in the cultures of spleen cells from mice primed 5 
days previously with varying doses of SRBC seemd to correlate well with that of 
helper activity (Fig. 1). It should be noted, however, that anti-hapten antibody 
response does not necessarily reflect the net helper activity, since the interac- 
tion between hapten-specific B cells and helper T cells may be strongly inter- 
fered with by the existence of carrier specific B cells (20, our unpublished data). 
The addition of anti-SRBC antiserum into the culture enhanced the anti-TNP 
antibody response of SRBC-primed spleen cells.  Such enhancement was more 
prominent in  the  culture  of spleen  cells from mice primed with  109  SRBC 
(unpublished data). The enhancement  of anti-hapten antibody response by anti- 
carrier antiserum may probably be attributable to the abrogation of competition 
between hapten-specific B cells and carrier-specific B cells for helper T cells, 
since the addition of anti-SRBC antiserum in the culture completely suppressed 
the generation of anti-SRBC PFC in vitro (Fig.  3). The net activity of helper T 
cells may be  measured only in such experimental systems in which B  cells 
directed to  the  carrier are eliminated.  Therefore, the  experimental data  on 
helper function as shown in Fig. 1 should be reconsidered with reference to the 
concept of the competition between hapten-reactive and carrier-reactive B cells. 
Either way, it was shown that helper activity was not suppressed by specific 
antiserum (Fig.  3 B).  On  the  other hand,  the  generation of Ag-V-PFC  was 
completely suppressed by the same dose of antiserum (Fig.  3 C). These results 
suggested that the antigen-reactive T cell detected as Ag-V-PFC belonged to a 
different population of cells from helper T cells, though the possibility could not 
be eliminated that the specific antibody blocked some metabolic stages of helper 
T cell in which VSV was replicated, without affecting helper function. It was 
also improbable that Ag-V-PFC represented the precursor of helper T cell. Thus, 
in mice primed with 105 SRBC, Ag-V-PFC developed to attain the peak 8 days 
after immunization (Fig.  5), while helper activity was the highest as early as 4 
days (18, our unpublished data). 402  VIRUS-REPLICATING  T  CELLS.  I. 
The suppressive effect of anti-SRBC serum and the absorbed serum on DTH 
against SRBC was thoroughly studied by Mackaness et al.  (13).  They showed 
that the suppressive effect of the absorbed serum was stronger than the native 
antiserum,  and that spleen cells from such suppressed mice were ineffective in 
transferring DTH to normal mice. In contrast, the absorbed serum had virtually 
no effect on the in vitro generation of Ag-V-PFC (Fig. 3). Though it is difficult to 
compare  the  results  obtained  in  in  vitro  experiments  with  those  in  in  vivo 
experiments, the dissociative effect of the absorbed serum suggested the differ- 
ence of Ag-V-PFC from effector cells in DTH. 
Kinetic studies (Figs. 5-7) showed that the latent period for the development 
of Ag-V-PFC became shorter as the immunizing doses increased. The peak level 
of Ag-V-PFC, on the other hand, did not necessarily depend on the immunizing 
doses. In the group primed with 105 or 107 SRBC, Ag-V-PFC developed after the 
level of DTH diminished.  Comparable level of Ag-V-PFC was observed in the 
group primed with 10  ~ SRBC, though DTH did not develop in this group. These 
results strongly suggested that Ag-V-PFC did not represent functional effector 
cells in DTH nor their precursors. 
Concerning the mechanisms of the enhancement of DTH by CY pretreatment, 
it was suggested that  CY pretreatment  eliminated the B-cell responses which 
had suppressive influence upon DTH (21, 22, see also Fig. 4). On the other hand, 
Askenase  et  al.  (27)  showed that  augmentation  of DTH  against  SRBC  was 
equally caused by the low dose of CY which had no effect on antibody response. 
Moreover, the  augmentation  of DTH by CY pretreatment  was also shown in 
mice immunized  with low dose of SRBC by which no  antibody response  was 
induced (27). Thus, the existence of suppressive influence upon DTH by the CY- 
sensitive cells other than antibody-forming cells was strongly suggested. Recent 
work by Askenase et al. (28) presented the evidence for the existence of suppres- 
sor T  cells involved in DTH against SRBC. In the present experiments,  treat- 
ment of mice with CY before immunization completely suppressed the develop- 
ment of Ag-V-PFC and markedly enhanced DTH when both were assayed on the 
same day  (Fig.  4).  Thus,  the Ag-V-PFC  seemed to have  similar  character  to 
suppressor T cells in DTH. Our unpublished data showed that injection of VSV 
together with antigen markedly augmented DTH against SRBC or other protein 
antigens without any noticeable effects on antibody production (manuscript in 
preparation).  This augmentative effect of VSV was antigen specific. Since VSV 
was shown to be a lytic virus (9), these observations again suggested that Ag-V- 
PFC may not represent the effector cells, but might represent the cells involved 
in the regulation of DTH. More detailed studies, of course, seem to be necessary 
before the exact nature  of lymphocytes which permit VSV replication  can be 
clarified. We hope that the clue for the further investigation can be found in the 
recent  study  by  Cantor  and  Simpson  (29)  in  which  it  was  shown  that  the 
induction of killer T cells was regulated by a distinct subpopulation of T cells. 
Summary 
Virus plaque-forming cell assay with vesicular stomatitis virus (VSV), which 
had been originally  introduced by Bloom and his  colleagues as a  tool for the 
enumeration of activated lymphocytes, was first applied to the immune response 
of mice to a widely used antigen, i.e. sheep red blood cells (SRBC). When spleen NAGAHIRO  MINATO  AND  YOSHIMOTO  KATSURA  403 
cells  taken  from  mice  previously primed with  SRBC  were  cultured in  the 
presence  of the  antigen,  lymphocytes capable  of replicating VSV  (antigen- 
induced virus plaque-forming cells, Ag-V-PFC) were generated in the culture. 
They seemed to appear as early as 1 day of  culture, and the peak was attained by 
the 2nd day. Most of Ag-V-PFC belonged to T-cell population, since 80-90%  of 
Ag-V-PFC was killed by the treatment of cultured cells with anti-thymocyte 
serum plus complement. 
In vitro generation of Ag-V-PFC seemed to be highly cross-reactive  (about 
40%) with a  related antigen (horse red blood cells). Ag-V-PFC detected in the 
present experiment may not represent helper T cells, effector T cells, or their 
precursors  because  of the  following:  (a)  The  generation  of Ag-V-PFC  was 
completely suppressed by the addition of anti-SRBC mouse serum in the culture, 
though the helper activity was apparently augmented by the same treatment. 
(b) Development of Ag-V-PFC was almost completely suppressed by the pre- 
treatment of mice with cyclophosphamide 2 days before immunization, by which 
delayed-type hypersensitivity (DTH) was markedly augmented.  (c)  After the 
immunization of mice, Ag-V-PFC began to develop just when the level of DTH 
declined, at which point helper activity of the spleen cells also diminished. A 
possible role of Ag-V-PFC in the immune response was discussed. 
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manuscript. 
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